The Role of Liposomal Bupivacaine in Reduction of Postoperative Pain After Transforaminal Lumbar Interbody Fusion: A Clinical Study.
Postoperative pain after transforaminal lumbar interbody fusion (TLIF) is a barrier to early mobility. Intraoperative local infiltration of anesthetic agents is standard practice to alleviate postoperative pain. Liposomal formulations may prolong the action of these anesthetic agents. The purpose of this study was to investigate the role of liposomal bupivacaine in postoperative pain control in patients undergoing unilateral, single-level TLIF. From a cohort of 74 patients, half received nonliposomal local anesthetic and half received liposomal bupivacaine (LB) (LB group) via local infiltration. Both groups received a standard postoperative analgesia regimen. Demographic information, postoperative pain scores (visual analog scale), analgesic consumption, length of stay, and complications were retrospectively collected. The area under the curve of cumulative pain scores was significantly lower in the LB group between 0 and 12 hours (15.0 ± 15.6 vs. 45.6 ± 21.1, P = 0.003) and between 12 and 24 hours (37.6 ± 20.6 vs. 48.4 ± 24.9, P = 0.05) after surgery. Significantly fewer narcotic equivalents were consumed in the LB group between 12 and 24 hours (16.0 ± 13.4 mg vs. 24.1 ± 19.7 mg intravenous morphine equivalents, P = 0.04). Length of stay was significantly shorter in the LB group than in the control group (3.1 ± 0.9 days vs. 4.3 ± 1.3 days, P < .001). LB may be a useful adjunct during unilateral TLIF for decreasing pain and narcotic consumption in the first 24 hours after surgery and may also decrease overall length of stay.